PHARMACOECONOMIC CLAIMS LIMITED TO "ECONOMIC CONSEQUENCES" IN FDA REFORM AMENDMENT; PHASE IV, PET DRUGS AMONG TOPICS MODIFIED FROM MARK-UP OF S 830
Executive Summary
The scope of pharmacoeconomic claims allowed under the Senate FDA reform bill would be limited to "the economic consequences, including the costs of the represented health outcomes" of a drug, under the floor version of the S 830 being debated the week of Sept. 8.